B+
Bull case
25%
Probability
Target price
$5.60
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
MRVI
Maravai LifesciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that Q1 was not just a one-time pop: TriLink base non-COVID revenue grew 15.4%, total TriLink revenue grew 65.1%, adjusted EBITDA turned positive at $20.3 million, free cash flow returned positive, and management raised both revenue and EBITDA guidance off the print. That combination supports a cleaner turnaround narrative than the prior filing-monitoring baseline.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
A meaningful portion of Q1 upside came from $14.3 million of high-volume CleanCap orders for commercial COVID vaccine programs, which may not be a durable quarterly run rate. [#8-K-2026-05-07]
Momentum
92
Value
49
Sentiment
17
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.30 · Bull $5.60 · Bear $3.10Analysis 2026-05-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $7.42
Why
Momentum92 · Δ7d +3.2
Value49 · Δ7d -0.0
Sentiment17 · Δ7d +4.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • A meaningful portion of Q1 upside came from $14.3 million of high-volume CleanCap orders for commercial COVID vaccine programs, which may not be a durable quarterly run rate. [#8-K-2026-05-07]
- • Analyst coverage is thin and peer comparables in the packet are loose, which lowers confidence in any post-earnings valuation read-through.
- • The bear case is that a meaningful part of the quarter came from $14.3 million of high-volume CleanCap orders tied to commercial COVID vaccine programs, while Cygnus growth was only 1.4% and China timing remained a drag.
Catalyst clock
2026-05-07
Q1 2026 beat with raised full-year guidance [#8-K-2026-05-07]
Lead driver: Value · See fundamentals
Momentum
92
9% active weight
Current posture
7d trendImproving
Δ7d
+3.2
Δ21d
+15.3
Value
49
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+8.2
Sentiment
17
62% active weight
Current posture
7d trendImproving
Δ7d
+4.1
Δ21d
-17.2
Why this grade
Composite grade F. Momentum 92.0 / Value 49.3 / Sentiment 16.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-09. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.30
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.10
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.47B
Beta
0.38
Shares Out
148.99M
P/E (TTM) · Derived
-10.9
P/S (TTM)
5.04
P/FCF (TTM) · Derived
-40.72
Rev YoY
+8.5%
EPS YoY
-69.4%
Gross Margin
+34.3%
Op Margin
-13.4%
Net Debt
$147.82M
Current Ratio
4.05
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data